| Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy YT Hsieh, EJ Gang, H Geng, E Park, S Huantes, D Chudziak, K Dauber, ... Blood, The Journal of the American Society of Hematology 121 (10), 1814-1818, 2013 | 137 | 2013 |
| Treatment of individuals who cannot receive blood products for religious or other reasons CD Scharman, D Burger, JJ Shatzel, E Kim, TG DeLoughery American journal of hematology 92 (12), 1370-1381, 2017 | 55 | 2017 |
| Off‐label use of 4‐factor prothrombin complex concentrate is common despite little known benefit: a retrospective study CD Scharman, JJ Shatzel, E Kim, TG DeLoughery European Journal of Haematology 101 (3), 349-353, 2018 | 10 | 2018 |
| Adjuvant CD49d blockade eradicates chemoresistant ALL YT Hsieh, E Park, E Jiang, K Dauber, D Chudziak, P Schaefer, L Klemm, ... Blood 116 (21), 869-869, 2010 | 4 | 2010 |
| Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care … SK Parsons, N Bhakta, AM Rodday, C Scharman, M André, M Federico, ... Journal of Clinical Oncology 38 (15_suppl), 12068-12068, 2020 | 3 | 2020 |
| Prognostication for advanced stage Hodgkin lymphoma (HL) in the modern era: a project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium AM Rodday, SK Parsons, C Scharman, R Advani, M Federico, ... Blood 136, 16-18, 2020 | 2 | 2020 |
| Autologous Stem Cell Transplant in the Era of Bortezomib-Based Induction for AL Amyloidosis Results in Improved Hematologic Response Rates: a Single Institution 11 Year Experience CD Scharman, JJ Shatzel, RT Maziarz, E Medvedova, A Stentz, G Rhyne, ... Blood 130, 4552, 2017 | 2 | 2017 |
| Preclinical Evaluation of Tysabri as a Novel Adjuvant Therapy against Drug Resistant B-ALL. YT Hsieh, E Jiang, C Scharman, E Waters, E Park, A Kadavallore, ... Blood 114 (22), 3089, 2009 | 2 | 2009 |
| The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL). SK Parsons, AM Rodday, C Scharman, M André, M Federico, ... Journal of Clinical Oncology 38 (15_suppl), e20019-e20019, 2020 | 1 | 2020 |
| The Off-Label Use of Four-Factor Prothrombin Complex Concentrate: A Single Institution Retrospective Study CD Scharman, E Kim, JJ Shatzel, TG Deloughery Blood 130, 3362, 2017 | 1 | 2017 |
| Harnessing multi-source data for individualized care in Hodgkin Lymphoma SK Parsons, AM Rodday, JN Upshaw, CD Scharman, Z Cui, Y Cao, ... Blood Reviews, 101170, 2024 | | 2024 |
| Durable Remission of Human Papillomavirus–Positive JAK2/PDL1/PDL2–Amplified Urethral Squamous Carcinoma With Sequential Chemotherapy and Immune … CD Scharman, ES Sokol, T Luongo, EM Genega, P Mathew JCO Precision Oncology 4, 860-864, 2020 | | 2020 |
| Occam's Razor Vs. Hickam's Dictum: Headache in an Immunocompromised Patient CD Scharman, AM Mansoor, AY O'Glasser SGIM Forum 41 (9), 8-9, 11, 2018 | | 2018 |
| Autologous Stem Cell Transplant in the Era of Bortezomib-Based Induction for AL Amyloidosis–A Single Institution 11 Year Experience CD Scharman, RT Maziarz, JJ Shatzel, E Medvedova, A Stentz, G Rhyne, ... Science Publishing Group Journal 1 (2), 1-15, 2018 | | 2018 |
| Targeting Survivin Using ICG-001 May Overcome Drug Resistance in Primary B-Cell Acute Lymphoblastic Leukemia. E Jiang, E Park, C Scharman, YT Hsieh, A Kadavallore, C Nguyen, ... Blood 114 (22), 3072, 2009 | | 2009 |
| Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALL E Jiang, M Yu, YT Hsieh, B DeLaTorre, A Kadavallore, C Scharman, ... Blood 112 (11), 2922, 2008 | | 2008 |
